RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:314652

Variant ABeta2M amyloidosis

high confidenceDisorder

Also known as: Autosomal dominant beta2-microglobulinic amyloidosis

Publications

51

42th percentile

Trials

0

Interventional, condition-specific

Researchers

176

Distinct authors in sample

Gene link

B2M

Strong

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare form of amyloidosis characterized by accumulation and extensive visceral deposition of an amyloidogenic variant of beta 2 microglobulin leading to gastrointestinal dysfunction, Sjögren syndrome and autonomic .

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

autosomal dominant beta2-microglobulinic amyloidosis

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Strong — B2M

  2. LiteraturePresent

    51 matched papers (32 in last 10 years) Source

  3. Phenotype characterisedPresent

    24 HPO annotations (e.g. Hepatic amyloidosis; Cutaneous amyloidosis; Amyloidosis of peripheral nerves) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (B2M).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

24

Associated phenotypes · MONDO:0017810

  • Hepatic amyloidosis
  • Cutaneous amyloidosis
  • Amyloidosis of peripheral nerves
  • Arthralgia of the hip
  • Gastrointestinal infarctions

Showing 5 of 24 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

51

51 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

51 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

32 in the last 10 years · high confidence · 42th percentile (publications denominator)

Phrase hits: 26 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

176

Distinct author names in 26 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Benson MD3 papers · 1989
    Papers in Europe PMC
  2. 02
    Booth SE2 papers · 2002
    Papers in Europe PMC
  3. 03
    Conneally PM2 papers · 1988
    Papers in Europe PMC
  4. 04
    Hawkins PN2 papers · 2002
    Papers in Europe PMC
  5. 05
    Park JH2 papers · 2016

    Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea.

    Papers in Europe PMC
  6. 06
    Wallace MR2 papers · 1988

    Department of Medical Genetics, Indiana University School of Medicine, Indianapolis.

    Papers in Europe PMC
  7. 07
    Agrawal V1 paper · 2024

    Division of Nephrology and Hypertension, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA.

    Papers in Europe PMC
  8. 08
    Almeida P1 paper · 2021

    Department of Internal Medicine, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal.

    Papers in Europe PMC
  9. 09
    Arenas J1 paper · 2020

    Laboratorio de Enfermedades Mitocondriales y Neurometabólicas, Instituto de Investigación Hospital 12 de Octubre (i+12), 28041 Madrid, Spain.

    Papers in Europe PMC
  10. 10
    Atashi M1 paper · 2022

    Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, TX 79409, USA.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

high confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

Broader category ABeta2M amyloidosis also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Broader category: ABeta2M amyloidosis

0

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Parent-category matching found a broader label but no interventional trials under it. How we count trials.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Variant ABeta2M amyloidosis — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Variant ABeta2M amyloidosis" OR "Autosomal dominant beta2-microglobulinic amyloidosis") OR ("B2M syndrome" OR "B2M-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Variant ABeta2M amyloidosis" OR "Autosomal dominant beta2-microglobulinic amyloidosis"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"ABeta2M amyloidosis"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T13:11:12.453Z